Mood eyewear Archives

Voila November-December 2024 Mood eyewear Blackfin Camano

Blackfin Launches New Fall/Winter 2024: Colour, Elegance, Comfort

Friday, November 29 2024 | 13 h 25 min | Frames Fashion

Blackfin launches its fall season with new collections and a campaign continuing the Spring/Summer theme The frames boast a minimalist design with...

Blackfin Renews Its Decade-long Partnership with Mood Eyewear for Exclusive Distribution in Canada

Thursday, October 24 2024 | 08 h 58 min | News

Blackfin, the Italian high-end Titanium eyewear company, announces the renewal of its partnership with Mood Eyewear, the exclusive distributor for...

Woodys : A Unique Version of “La Dolce Vita”

Thursday, September 12 2024 | 12 h 26 min | Frames Fashion

Woodys presents La Dolce Vita, a new campaign inspired by this famous lifestyle for its Fall-winter collection, adding 44 new models to its main...

Visionario’s “Breaking News” Campaign: A Tribute to Sunglasses

Monday, July 15 2024 | 12 h 42 min | Frames Fashion

Visionario’s new campaign, “Breaking News”, portays the celebrity-paparazzi relationship International outlets promote these images on a daily...

Woodys Unveils Colorado, the Spring-Summer Collection Campaign

Monday, May 27 2024 | 13 h 02 min | Frames Fashion

Woodys presents Colorado, a campaign set in the desert full of fashion and style The spring-summer collection features LEXI 03 These hexagonal...

1 2 3 4 Next »

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Tag: Mood eyewear

Blackfin Launches New Fall/Winter 2024: Colour, Elegance, Comfort

Blackfin Renews Its Decade-long Partnership with Mood Eyewear for Exclusive Distribution in Canada

Woodys : A Unique Version of “La Dolce Vita”

Visionario’s “Breaking News” Campaign: A Tribute to Sunglasses

Woodys Unveils Colorado, the Spring-Summer Collection Campaign

Featured Posts

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement